Trial Profile
A Multicenter, Randomized, Open-Label, Parallel Group Phase 1 Pharmacokinetic Comparability Study of Benralizumab Administrated Using Accessorized Pre-Filled Syringe (APFS) or Autoinjector (AI) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Acronyms AMES
- Sponsors AstraZeneca
- 04 Oct 2019 Results presented in an AstraZeneca media release.
- 04 Oct 2019 According to an AstraZeneca media release, the US Food and Drug Administration (FDA) has approved the self administration of FASENRA (benralizumab) in a pre-filled, single use auto-injector.This approval is supported by data from Phase III GRECO and Phase I AMES trials.
- 25 Feb 2019 Results presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology